N/A
N=335
Evaluating the Impact of the Bridge Clinic in Patients With Opioid Use Disorder
Opioid Use · Opioid-use Disorder
Bottom Line
View on ClinicalTrials.gov: NCT04084392 ↗Enrolled (actual)
335
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcome: Primary: Hospital Length of Stay — 232.1; 215.0 Hours
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bridge Clinic (Other); Usual Care (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vanderbilt University Medical Center
- Primary completion
- Sep 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hospital Length of Stay |
232.1; 215.0 | — |
| SECONDARY Combined Cost of Index Admission and Subsequent Admissions During the Study Period |
1705.28; 9481.93 | — |
| SECONDARY Number of Participants With Successful Care Linkage |
19; 45; 13; 11 | — |
| SECONDARY Number of MAT Prescriptions Filled by Participant |
1; 10 | — |
| SECONDARY Readmissions and Emergency Department (ED) Visits |
0; 0 | — |
| SECONDARY Hospital and ED Free Days |
112; 112 | — |
| SECONDARY Mortality |
4; 2 | — |
| SECONDARY Recurrent Opioid Use |
15; 23 | — |
| SECONDARY Overdose |
4; 1 | — |
| SECONDARY Quality of Life - Schwartz Outcome Scale-10 (SOS10). |
41.5; 47 | — |
| SECONDARY Opioid Use Within 30 Days |
2; 2; 4; 0; 7; 17 | — |
Summary
This study aims to determine whether referral to the Bridge Clinic reduces overall index hospital length of stay when compared to direct referral to a long-term outpatient addiction provider for patients with active opioid use disorder (OUD) being considered for medications-for-addiction treatment (MAT).
Eligibility Criteria
Inclusion Criteria
- Inpatients at VUH with active OUD being considered for MAT.
- Patient accepting a transitional prescription for buprenorphine-naloxone or IM naltrexone whose outpatient plans are not fixed
Exclusion Criteria
- Deemed ineligible for referral to outpatient Bridge Clinic by the Addiction Consult Team (examples include but are not limited to patients with severe, active co-occurring psychiatric disorders requiring a higher level of psychiatric care or patients for whom methadone maintenance is deemed the best choice of MAT).
- Patients previously randomized in this study.
Data sourced from ClinicalTrials.gov (NCT04084392). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.